We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merus NV | TG:2GH | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|
| -0.60 | -1.36% | 43.40 | 0.00 | 22:50:13 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 42.80 | 43.80 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | 0 | 43.40 | EUR |
| Date | Time | Source | Headline |
|---|---|---|---|
| 04/12/2024 | 21:55 | UKREG | Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+.. |
| 02/12/2024 | 13:00 | UKREG | Merus and Partner Therapeutics Announce License Agreement for the U.S... |
| 02/12/2024 | 13:00 | UKREG | Merus et Partner Therapeutics annoncent un contrat de licence en vue de la.. |
| 02/12/2024 | 13:00 | UKREG | Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung.. |
| 01/12/2024 | 16:05 | UKREG | Merus annonce la publication d’un résumé sur le pétosemtamab en tant que.. |
| 01/12/2024 | 16:05 | UKREG | Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment.. |
| 01/12/2024 | 16:05 | UKREG | Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines.. |
| 07/11/2024 | 13:23 | UKREG | Merus annonce sa participation aux prochaines journées Investisseurs |
| 07/11/2024 | 13:23 | UKREG | Merus hält Vorträge auf bevorstehenden Investorenkonferenzen |
| 05/11/2024 | 22:39 | UKREG | La FDA octroie à Merus un report de la date PDUFA pour le zénocutuzumab |
Merus NV (2GH) Share Charts1 Year Merus NV Chart |
|
1 Month Merus NV Chart |
Intraday Merus NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
